Implementation of Real-Time MR-guided Interstitial Brachytherapy for Gynecological Cancer

Kitty Chan 1, Anna Simeonov 2, Anne Di Tomasso 5, Gerald O’Leary 4, Ana Lopez Filici 5, Alexandra Rink 6, Akbar Beiki-Ardakani 3, Jette Borg 7, Jennifer Croke 8, Anthony Fyles 9, Kathy Han 10, Michael Milosevic 11

1. Radiation Medicine Program, Princess Margaret Cancer Centre, Princess Margaret Cancer Centre 2. Radiation Medicine Program, Princess Margaret Cancer Centre, University of Toronto, Ontario 3. Radiation Medicine Program, Princess Margaret Cancer Centre, Princess Margaret Cancer Centre, Toronto, Ontario 4. Department of Anesthesia, University Health Network, University of Toronto, Ontario 5. Department of Anesthesia, University Health Network, Canada, University Health Network, Canada 6. Radiation Medicine Program, Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada 7. Radiation Medicine Program, Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario 8. Radiation Medicine Program, Princess Margaret Hospital, University of Toronto, Toronto, Canada 9. Radiation Medicine Program / Radiation Oncology, Princess Margaret Hospital/University Health Network / University of Toronto 10. Radiation Medicine Program, Princess Margaret Cancer Centre, Toronto, ON 11. Radiation Medicine Program / Radiation Oncology, University of Toronto

Corresponding author: Kitty Chan, kitty.chan@rmp.uhn.on.ca

Categories: Radiation Oncology
Keywords: mr-guided brachytherapy, cervix cancer, process development, clinical implementation

How to cite this poster

Abstract

Objective(s)

In an integrated MR-guided brachytherapy (MRgBT) suite, the patient remains in one location and a MR system mounted on ceiling rails move in and out of the interventional suite as needed. General anesthesia (GA), applicator insertion, MR-image acquisition and high-dose-rate (HDR) BT delivery can take place in the same room. Real-time MR-image acquisition has the potential to substantially improve overall procedure efficiency and interstitial needle placement (hence improve target coverage and dose sparing to organs at risk). The aim of this work is to describe our experience in implementing our first real-time MR-guided interstitial BT treatment for a gynecological (GYN) patient.

Methods

Process mapping defining tasks and workflow was completed and checklists development was done. Safety policies/procedures regarding radiation and MR safety for staff and patients were established. Interdisciplinary team meetings and structured walk-throughs with anesthesiologists, anesthesia assistants, radiation oncologists, nurses, MR technologists and brachytherapists were held to design a safe procedure. Equipment flow and room transition were proposed: surgical, MR and radiation safety checks were incorporated in the intra-op MR-guided BT procedure. Lastly, mock emergency scenarios were discussed prior to scheduling the first patient.
Results

Four safety time-outs were executed: pre-anesthesia, pre-applicator insertion, pre-MRI imaging & pre-HDR treatment. Four checklists: pre-drape & pre-MR scan, one surgical instrument and one anesthesia equipment/supplies checklists were developed to ensure surgical and MR safety. A 65 year-old woman with vaginal recurrence of endometrial cancer underwent real-time MR-guided interstitial BT using Syed-Neblett template under GA in the MRgBT suite. Total procedure time was 3 hours and 15 min (from GA induction to completion of HDR BT delivery): applicator and template insertion (48 mins), MR-guided needle insertion (41 mins), contouring and planning (30 mins), HDR BT delivery (8 mins) and recovery (37 mins). Time savings of 65% was achieved compared with procedure performed in a non-integrated MRgBT suite setting (9 hrs 6 mins). For a 7 Gy prescription, dosimetry improved from first insertion (without real-time MR) to second insertion (with real-time MR): the D90%, V100 for CTV_{HR} & CTV_{IR} : 7.7 to 12.6Gy, 83% to 99% & 4.1 to 6.7Gy, 91% to 100%. Changes to D2cc for Sigmoid, Rectum, Small Bowel & Bladder were as follows: 0.47 to 1.12Gy, 4.9 to 3.6Gy, 1.7 to 3.6Gy & 3.8 to 5.58Gy. The EQD2 dose combining external beam radiotherapy 45 Gy (1.8 Gy/fraction) and two HDR BT for CTV_{HR} & CTV_{IR}, Sigmoid, Rectum, Small Bowel & Bladder were: 90 Gy, 68 Gy, 46 Gy, 65 Gy, 59 Gy & 63 Gy.

Conclusions

Our initial experience demonstrates that real-time MR-guided interstitial BT treatment for GYN cancer is feasible in an integrated MRgBT interventional suite; substantial efficiency and target coverage were improved as a result.